Organovo Holdings, Inc. (NASDAQ:ONVO) tinted loss of 0% (0 points) to US$1. The volume of 0.25 Million shares climbed down over an trading activity of 540.67 Million shares. EPS ratio determined by looking at last 12 month figures is -0.24. Over the same time span, the stock marked US$2.09 as its best level and the lowest price reached was US$0.9. The corporation has a market cap of US$114.8 Million.
Organovo Holdings, Inc. (NASDAQ:ONVO)’s earnings per share has been growing at a -4.4 percent rate over the past 5 year when average revenue increase was noted as 84.6 percent. The return on equity ratio or ROE stands at -67.5 percent while most common profitability ratio return on investment (ROI) was -79.1 percent. The company’s institutional ownership is monitored at 36.7 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 81.1 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.8. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
OncoSec Medical Incorporated (NASDAQ:ONCS) is worth US$38.1 Million and has recently fallen 0% to US$0.6. The latest exchange of 0.37 Million shares is below its average trading activity of 1.31 Million shares. The day began at US$0.63 but the price moved to US$0.63 at one point during the trading and finally capitulating to a session high of US$0.63. The stock tapped a 52-week high of US$2.21 while the mean 12-month price target for the shares is US$4.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.3, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 6.2%. With an institutional ownership near 11.5%, it carries an earnings per share ratio of -0.88.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.33.